Clinical Trial Detail

NCT ID NCT03504163
Title Pembrolizumab (MK-3475) as First-line Therapy for Carcinoma in Situ (Tis) Non-Muscle-Invasive Bladder Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications
Therapies

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.